Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

Francesca Pettinella; Barbara Mariotti; Chiara Lattanzi; Kirsten Bruderek; Marta Donini; Sara Costa; Olivia Marini; Giulia Iannoto; Sara Gasperini; Elena Caveggion; Monica Castellucci; Federica Calzetti; Francisco Bianchetto-Aguilera; Elisa Gardiman; Matteo Giani; Stefano Dusi; Maurizio Cantini; Aurora Vassanelli; Denise Pavone; Michele Milella; Sara Pilotto; Pamela Biondani; Benedikt Höing; Marie Carolin Schleupner; Timon Hussain; Boris Hadaschik; Cordelia Kaspar; Carlo Visco; Cristina Tecchio; Leo Koenderman; Flavia Bazzoni; Nicola Tamassia; Sven Brandau; Marco A. Cassatella; Patrizia Scapini

doi:10.1016/j.xcrm.2023.101380

Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

Francesca Pettinella, Barbara Mariotti, Chiara Lattanzi, Kirsten Bruderek, Marta Donini, Sara Costa, Olivia Marini, Giulia Iannoto, Sara Gasperini, Elena Caveggion, Monica Castellucci, Federica Calzetti, Francisco Bianchetto-Aguilera, Elisa Gardiman, Matteo Giani, Stefano Dusi, Maurizio Cantini, Aurora Vassanelli, Denise Pavone, Michele MilellaSara Pilotto, Pamela Biondani, Benedikt Höing, Marie Carolin Schleupner, Timon Hussain, Boris Hadaschik, Cordelia Kaspar, Carlo Visco, Cristina Tecchio, Leo Koenderman, Flavia Bazzoni, Nicola Tamassia, Sven Brandau, Marco A. Cassatella^*, Patrizia Scapini^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

Precise molecular characterization of circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) is hampered by their mixed composition of mature and immature cells and lack of specific markers. Here, we focus on mature CD66b⁺CD10⁺CD16⁺CD11b⁺ PMN-MDSCs (mPMN-MDSCs) from either cancer patients or healthy donors receiving G-CSF for stem cell mobilization (GDs). By RNA sequencing (RNA-seq) experiments, we report the identification of a distinct gene signature shared by the different mPMN-MDSC populations under investigation, also validated in mPMN-MDSCs from GDs and tumor-associated neutrophils (TANs) by single-cell RNA-seq (scRNA-seq) experiments. Analysis of such a gene signature uncovers a specific transcriptional program associated with mPMN-MDSC differentiation and allows us to identify that, in patients with either solid or hematologic tumors and in GDs, CD52, CD84, and prostaglandin E receptor 2 (PTGER2) represent potential mPMN-MDSC-associated markers. Altogether, our findings indicate that mature PMN-MDSCs distinctively undergo specific reprogramming during differentiation and lay the groundwork for selective immunomonitoring, and eventually targeting, of mature PMN-MDSCs.

Original language	English
Article number	101380
Journal	Cell Reports Medicine
Volume	5
Issue number	2
DOIs	https://doi.org/10.1016/j.xcrm.2023.101380
Publication status	Published - 20 Feb 2024

Keywords

biomarkers
cancer patients
G-CSF
neutrophils
PMN-MDSCs

Access to Document

10.1016/j.xcrm.2023.101380Licence: CC BY-NC-ND

mmc5 (1)Final published version, 11.1 MBLicence: CC BY-NC-ND

Cite this

Pettinella, F., Mariotti, B., Lattanzi, C., Bruderek, K., Donini, M., Costa, S., Marini, O., Iannoto, G., Gasperini, S., Caveggion, E., Castellucci, M., Calzetti, F., Bianchetto-Aguilera, F., Gardiman, E., Giani, M., Dusi, S., Cantini, M., Vassanelli, A., Pavone, D., ... Scapini, P. (2024). Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors. Cell Reports Medicine, 5(2), Article 101380. https://doi.org/10.1016/j.xcrm.2023.101380

@article{183749750e2b461891abc68ecf82f000,

title = "Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors",

abstract = "Precise molecular characterization of circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) is hampered by their mixed composition of mature and immature cells and lack of specific markers. Here, we focus on mature CD66b+CD10+CD16+CD11b+ PMN-MDSCs (mPMN-MDSCs) from either cancer patients or healthy donors receiving G-CSF for stem cell mobilization (GDs). By RNA sequencing (RNA-seq) experiments, we report the identification of a distinct gene signature shared by the different mPMN-MDSC populations under investigation, also validated in mPMN-MDSCs from GDs and tumor-associated neutrophils (TANs) by single-cell RNA-seq (scRNA-seq) experiments. Analysis of such a gene signature uncovers a specific transcriptional program associated with mPMN-MDSC differentiation and allows us to identify that, in patients with either solid or hematologic tumors and in GDs, CD52, CD84, and prostaglandin E receptor 2 (PTGER2) represent potential mPMN-MDSC-associated markers. Altogether, our findings indicate that mature PMN-MDSCs distinctively undergo specific reprogramming during differentiation and lay the groundwork for selective immunomonitoring, and eventually targeting, of mature PMN-MDSCs.",

keywords = "biomarkers, cancer patients, G-CSF, neutrophils, PMN-MDSCs",

author = "Francesca Pettinella and Barbara Mariotti and Chiara Lattanzi and Kirsten Bruderek and Marta Donini and Sara Costa and Olivia Marini and Giulia Iannoto and Sara Gasperini and Elena Caveggion and Monica Castellucci and Federica Calzetti and Francisco Bianchetto-Aguilera and Elisa Gardiman and Matteo Giani and Stefano Dusi and Maurizio Cantini and Aurora Vassanelli and Denise Pavone and Michele Milella and Sara Pilotto and Pamela Biondani and Benedikt H{\"o}ing and Schleupner, {Marie Carolin} and Timon Hussain and Boris Hadaschik and Cordelia Kaspar and Carlo Visco and Cristina Tecchio and Leo Koenderman and Flavia Bazzoni and Nicola Tamassia and Sven Brandau and Cassatella, {Marco A.} and Patrizia Scapini",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2024",

month = feb,

day = "20",

doi = "10.1016/j.xcrm.2023.101380",

language = "English",

volume = "5",

number = "2",

}

Pettinella, F, Mariotti, B, Lattanzi, C, Bruderek, K, Donini, M, Costa, S, Marini, O, Iannoto, G, Gasperini, S, Caveggion, E, Castellucci, M, Calzetti, F, Bianchetto-Aguilera, F, Gardiman, E, Giani, M, Dusi, S, Cantini, M, Vassanelli, A, Pavone, D, Milella, M, Pilotto, S, Biondani, P, Höing, B, Schleupner, MC, Hussain, T, Hadaschik, B, Kaspar, C, Visco, C, Tecchio, C, Koenderman, L, Bazzoni, F, Tamassia, N, Brandau, S, Cassatella, MA & Scapini, P 2024, 'Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors', Cell Reports Medicine, vol. 5, no. 2, 101380. https://doi.org/10.1016/j.xcrm.2023.101380

TY - JOUR

T1 - Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

AU - Pettinella, Francesca

AU - Mariotti, Barbara

AU - Lattanzi, Chiara

AU - Bruderek, Kirsten

AU - Donini, Marta

AU - Costa, Sara

AU - Marini, Olivia

AU - Iannoto, Giulia

AU - Gasperini, Sara

AU - Caveggion, Elena

AU - Castellucci, Monica

AU - Calzetti, Federica

AU - Bianchetto-Aguilera, Francisco

AU - Gardiman, Elisa

AU - Giani, Matteo

AU - Dusi, Stefano

AU - Cantini, Maurizio

AU - Vassanelli, Aurora

AU - Pavone, Denise

AU - Milella, Michele

AU - Pilotto, Sara

AU - Biondani, Pamela

AU - Höing, Benedikt

AU - Schleupner, Marie Carolin

AU - Hussain, Timon

AU - Hadaschik, Boris

AU - Kaspar, Cordelia

AU - Visco, Carlo

AU - Tecchio, Cristina

AU - Koenderman, Leo

AU - Bazzoni, Flavia

AU - Tamassia, Nicola

AU - Brandau, Sven

AU - Cassatella, Marco A.

AU - Scapini, Patrizia

PY - 2024/2/20

Y1 - 2024/2/20

N2 - Precise molecular characterization of circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) is hampered by their mixed composition of mature and immature cells and lack of specific markers. Here, we focus on mature CD66b+CD10+CD16+CD11b+ PMN-MDSCs (mPMN-MDSCs) from either cancer patients or healthy donors receiving G-CSF for stem cell mobilization (GDs). By RNA sequencing (RNA-seq) experiments, we report the identification of a distinct gene signature shared by the different mPMN-MDSC populations under investigation, also validated in mPMN-MDSCs from GDs and tumor-associated neutrophils (TANs) by single-cell RNA-seq (scRNA-seq) experiments. Analysis of such a gene signature uncovers a specific transcriptional program associated with mPMN-MDSC differentiation and allows us to identify that, in patients with either solid or hematologic tumors and in GDs, CD52, CD84, and prostaglandin E receptor 2 (PTGER2) represent potential mPMN-MDSC-associated markers. Altogether, our findings indicate that mature PMN-MDSCs distinctively undergo specific reprogramming during differentiation and lay the groundwork for selective immunomonitoring, and eventually targeting, of mature PMN-MDSCs.

AB - Precise molecular characterization of circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) is hampered by their mixed composition of mature and immature cells and lack of specific markers. Here, we focus on mature CD66b+CD10+CD16+CD11b+ PMN-MDSCs (mPMN-MDSCs) from either cancer patients or healthy donors receiving G-CSF for stem cell mobilization (GDs). By RNA sequencing (RNA-seq) experiments, we report the identification of a distinct gene signature shared by the different mPMN-MDSC populations under investigation, also validated in mPMN-MDSCs from GDs and tumor-associated neutrophils (TANs) by single-cell RNA-seq (scRNA-seq) experiments. Analysis of such a gene signature uncovers a specific transcriptional program associated with mPMN-MDSC differentiation and allows us to identify that, in patients with either solid or hematologic tumors and in GDs, CD52, CD84, and prostaglandin E receptor 2 (PTGER2) represent potential mPMN-MDSC-associated markers. Altogether, our findings indicate that mature PMN-MDSCs distinctively undergo specific reprogramming during differentiation and lay the groundwork for selective immunomonitoring, and eventually targeting, of mature PMN-MDSCs.

KW - biomarkers

KW - cancer patients

KW - G-CSF

KW - neutrophils

KW - PMN-MDSCs

UR - http://www.scopus.com/inward/record.url?scp=85182996587&partnerID=8YFLogxK

U2 - 10.1016/j.xcrm.2023.101380

DO - 10.1016/j.xcrm.2023.101380

M3 - Article

C2 - 38242120

AN - SCOPUS:85182996587

SN - 2666-3791

VL - 5

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 2

M1 - 101380

ER -

Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this